Sarepta Therapeutics (SRPT) reported 467.17millioninrevenueforthequarterendedSeptember2024,representingayear−over−yearincreaseof40.80.62 for the same period compares to -0.46ayearago.ThereportedrevenuecomparestotheZacksConsensusEstimateof399.88 million, representing a surprise of +16.83%. The company delivered an EPS surprise of +513.33%, with the consensus EPS estimate being -$0.15.While investors closely watch year-over-year changes in headline numbers -- revenue ...